Viral clearance studies are mandated prior to entering clinical trials
and for commercial launch of biopharmaceuticals. These studies are a
key component of risk mitigation to reduce the potential for iatrogenic
transmission of pathogenic viruses. This paper reviews regulatory
guidance and practical strategies for designing viral clearance
studies. Essential elements for a developmental phase-appropriate viral
clearance package are detailed.
No comments:
Post a Comment